-
Meihua Medtech Secures Over RMB 100M in Series B Financing Led by Eight Roads and Sunland
•
China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider, has reportedly raised over RMB 100 million (USD 14.3 million) in a Series B financing round. The round was led by Eight Roads and Sunland Fund, with contributions from Zhuhai Hi tech Financial Investment and…
-
InnerMedical Secures RMB 300M in Series D Funding Led by Green Pine and Simiao
•
InnerMedical Co., Ltd, a leading chronic disease diagnosis and treatment solutions provider based in Shenzhen, has reportedly raised close to RMB 300 million (USD 42.9 million) in a Series D financing round. The round was led by Green Pine Capital Partners and Simiao Capital, with participation from Cornerstone Investment, Chengshang…
-
Novartis China Establishes Health Development Fund in Boao Lecheng
•
Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant move aimed at bolstering health development, advancing societal improvement, and facilitating common prosperity in China through national-level charitable activities. Registered at the Boao Lecheng Medical Tourism Pilot Zone, this initiative makes Novartis the first in…
-
Henlius’ Serplulimab Receives Orphan Drug Designation in Europe for SCLC
•
Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the European Committee for its HanSiZhuang (serplulimab) for the treatment of small-cell lung cancer (SCLC). The programmed death-1 (PD-1) inhibitor, previously awarded ODD status in the US for the same indication, is expected to become the…
-
XingImaging and Mitro Biotech Partner for Contract Research Services in China
•
US-based XingImaging LLC and China-based Mitro Biotech Co., Ltd have announced a partnership to provide contract research services in China. The collaboration aims to partner with global pharma and biotech companies in the target market, focusing on neuroscience and oncology. XingImaging: Specializing in Radiotracer Production and PET AcquisitionXingImaging, based in…
-
Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303
•
China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US major Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) to investigate Doer Bio’s anti-Claudin18.2 antibody DR30303 in combination with MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with gastric or gastroesophageal junction cancer (GC/GEJ). Under the…
-
WuXi Biologics’ Shanghai Subsidiary Removed from US UVL
•
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd has been removed from the Unverified List (UVL) by the US Department of Commerce, effective December 16, 2022. Consequently, both of WuXi Bio’s subsidiaries previously on the list have…
-
Liaoning Publishes Fourth Round of Volume-Based Procurement Winning Bids
•
The Liaoning drug and medical consumables centralized procurement website has published the fourth round of volume-based procurement (VBP) winning bids among the “eight provinces and two regions.” The list includes a total of 18 drug specifications with an average price reduction of 59.53%, and is open for public feedback until…
